2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis.

Amyloidosis Cardiac Genetics Heart failure Heart failure with preserved ejection fraction Hereditary Transthyretin

Journal

Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739

Informations de publication

Date de publication:
02 Apr 2024
Historique:
received: 09 11 2023
accepted: 17 11 2023
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 3 4 2024
Statut: aheadofprint

Résumé

Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.

Identifiants

DOI: 10.1016/j.hlc.2023.11.027 PMID: 38570258
pubmed: 38570258
pii: S1443-9506(24)00123-9
doi: 10.1016/j.hlc.2023.11.027
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest NB: Novartis, Pfizer—research, Bristol Myers Squibb—advisory board. JLH: Pfizer—advisory board, clinical trials involvement. SDJG: Pfizer, BridgBio, Alexion/Astrazeneca, Ionis, Intellia, Attralus—honoria for speaking engagements, advisory board or steering committee payments, clinical trials involvement. PM: Jansen, Pfizer—research funding/clinical trials involvement. LT: Boehringer Ingelheim, Novartis, Sanofi Genzyme—advisory board, Jansen, Pfizer, Bayer—research funding. No relevant conflicts of interest to declare: DF, JG, DK, FK, KL, DR, HS, TS.

Auteurs

Nicole K Bart (NK)

Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. Electronic address: http://www.twitter.com/drnikkibart.

Diane Fatkin (D)

Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.

James Gunton (J)

Department of Cardiology, Flinders Medical Centre, Adelaide, SA, Australia.

James L Hare (JL)

Department of Cardiology, Alfred Health, Melbourne, and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, Australia.

Dariusz Korczyk (D)

Department of Cardiology, The Princess Alexandra Hospital, Brisbane, Qld, Australia.

Fiona Kwok (F)

Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.

Kaitlyn Lam (K)

Department of Cardiology, Western Australia Advanced Heart Failure and Cardiac Transplant Service, Perth, WA, Australia.

David Russell (D)

Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia.

Hasib Sidiqi (H)

Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.

Tim Sutton (T)

Te Whatu Ora Counties Manukau, Auckland; and Department of Cardiology, Auckland, Aotearoa, New Zealand.

Simon D J Gibbs (SDJ)

Department of Haematology, Eastern Health; Epworth Freemasons; and Monash University, Melbourne, Vic, Australia.

Peter Mollee (P)

Queensland Amyloidosis Centre, The Princess Alexandra Hospital, Brisbane; and, School of Medicine, University of Queensland, Brisbane, Qld, Australia.

Liza Thomas (L)

Department of Cardiology, Westmead Hospital, Sydney; Westmead Clinical School, University of Sydney, Sydney; and, South West Clinical School, University of New South Wales, Sydney, NSW, Australia. Electronic address: Liza.Thomas@sydney.edu.au.

Classifications MeSH